top of page
Browse by category
Search
Wegovy may have highest ischaemic optic neuropathy and sight loss risk
Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ischaemic optic neuropathy (ION) and sudden sight loss of the semaglutide drugs, according to a study by researchers from the University of Ottawa, Ottawa, Ontario, Canada. They found that the risk is almost five times higher with Wegovy than it is with Ozempic, and three times greater in men than it is in women. ION is caused by inadequate/interrupted blood flow to the optic nerve, resulting in sudden vis
GLP-1s associated with higher risk of major depression, increased risk for anxiety and an elevated risk for suicidal behaviour
Patients on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Victoza (Liraglutide 1.8mg), Saxenda (Liraglutide 3mg), Ozempic...
FDA approves Wegovy for CVD risk reduction in people with overweight or obesity and established cardiovascular disease
The FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing...
European Medicines Agency to discuss anaesthesia risk for weight-loss drugs
The European Medicines Agency (EMA) will assess the risk that patients on weight loss drugs such as semaglutide and tirzepatide may...
Journal Watch 13/09/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Novo Nordisk to protect US patients from unlawful sales of non-FDA approved ‘semaglutide medicines’
Novo Nordisk is taking multiple actions to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and...
FDA approves Novo Nordisk’s Wegovy (semaglutide 2.4 mg) for weight management
The FDA has approved Novo Nordisk’s Wegovy (the brand name for once-weekly semaglutide 2.4mg injection in the US) for chronic weight...
Browse by tag
bottom of page